ClinicalTrials.gg
Enrolling by invitationNCT04646187FREEUpdated Jan 6, 2025

De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease

A Phase 4 interventional study of Infliximab and Adalimumab in Inflammatory Bowel Diseases, Crohn Disease and Colitis, Ulcerative, sponsored by University Medical Center Groningen. Enrolling by invitation at 7 sites in 3 countries. Open to participants aged 12 Years to 25 Years. Per ClinicalTrials.gov, last updated 2025-01-06.

Sponsored by University Medical Center Groningen · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
12 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing infliximab in Inflammatory Bowel Diseases — 6 open to participants now, 7 under way, none of them phase 3. Infliximab · Inflammatory Bowel Diseases.

Planned enrollment
5th of 20
148 · median 83
Started
2021
with 1 other
Phase 4
10 of 20
4 open now
Registered
11th of 20
by date

Among the 20 studies testing infliximab in Inflammatory Bowel Diseases, this one is the 5th largest by planned enrollment, is one of 2 that started in 2021, is one of 10 in phase 4, and was the 11th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

6 of the 20 studies testing infliximab in Inflammatory Bowel Diseases are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About infliximab

Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 12 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing infliximab in Inflammatory Bowel Diseases, or all of them as a file.
02

Study summary

BACKGROUND/RATIONALE:

Treatment outcomes of patients with inflammatory bowel disease (IBD) have improved enormously during the past decade due to the use of anti-tumour necrosis factor (anti-TNF) therapy. As a result, 67 to 91% of paediatric patients and 66% of adult patients is still in sustained remission two years after the initiation of anti-TNF therapy. Prolonged use of anti-TNFs comes with disadvantages such as dose dependent susceptibility to infections and dermatological adverse effects. Preliminary, mostly uncontrolled studies suggest that dose reduction by dosing interval lengthening is a realistic option in a relevant proportion of patients with IBD, provided that intensive follow-up is applied.

OBJECTIVE:

To evaluate whether a faecal calprotectin (FC) guided strategy of anti-TNF dosing interval lengthening is non-inferior in maintaining remission in patients with IBD, compared with an unchanged dosing interval.

Read the detailed description

STUDY DESIGN:

International, multi-centre, prospective, partially randomised patient-preference trial.

STUDY POPULATION:

Study population: Eligible patients are aged 12-25 years with luminal Crohn's disease (CD) or ulcerative colitis (UC), who have three consecutive faecal calprotectin (FC) results in the target range (i.e. \<250 µg/g for CD patients; \<150 µg/g for UC patients) over a period of 6 months at study entry or recently confirmed endoscopic remission.

DE-ESCALATION STRATEGY:

In patients treated with adalimumab, the dosing interval will be lengthened from 2 to 3 weeks. In patients treated with infliximab, the dosing interval will be lengthened from 8 to 12 weeks. FC rapid tests will be performed every 4 weeks and rapid tests for anti-TNF trough levels will be performed every 12 weeks.

MAIN STUDY ENDPOINTS:

The primary outcome is the cumulative incidence of out-of-range FC results at 48 weeks follow-up. Secondary endpoints include time to get out-of-range FC results, cumulative incidence of anti-TNF associated adverse effects, proportion of patients progressing from out-of-range FC to loss-of-response and identification of predictors of successful de-escalation.

ETHICAL CONSIDERATIONS:

Patients with reduced anti-TNF exposure may have a higher risk of out-of-range FC results and, on the other hand, may benefit from fewer hospital visits or injections and possibly a decrease in adverse effects of anti-TNF therapy. Tight monitoring of FC levels (i.e. 4-weekly) will allow institution of re-escalation before the patient manifests clinical signs of relapse. This study cannot be conducted without the participation of minors and young adults, who typically have a short disease duration. Early treatment with anti-TNF agents possibly modifies the course of their disease, which makes provision for safe deescalation.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Crohn Disease
  • Colitis, Ulcerative

Keywords

  • Infliximab
  • Adalimumab
  • Tumor Necrosis Factor-alpha
  • Inflammatory Bowel Diseases
  • Crohn Disease
  • Colitis, Ulcerative
04

Who can participate

Ages eligible
12 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 12-25 years
  • Diagnosed with luminal Crohn's disease or ulcerative colitis
  • Treated with either 8-weekly infliximab or 2-weekly adalimumab
  • Current anti-TNF agent as first ever anti-TNF agent or prior anti-TNF agent discontinued for reason other than primary non-response or secondary loss-of-response
  • No previous attempts to lengthen the dosing interval
  • Three consecutive faecal calprotectin (FC) results in the target range (i.e. \<250 μg/g for CD patients; \<150 μg/g for UC patients) in the previous 6 months or confirmed endoscopic remission within 2 months before study entry (i.e. simple endoscopic score for Crohn's disease (SES-CD) \<3 points for CD patients; ulcerative colitis endoscopic index of severity (UCEIS) ≤1 point for UC patients)
  • Absence of symptoms associated with active IBD (judged by the local IBD-team)
  • Written granted

Exclusion criteria

Exclusion Criteria:

  • Perianal fistula
  • Presence of ileostomy or ileoanal pouch (as FC cut-off is not validated for small bowel faeces)
  • Any inflammatory comorbidity, such as rheumatoid arthritis
  • Current treatment with (prednisone or budesonide)
  • Current pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Intervention group

    In patients treated with adalimumab, the dosing interval will be lengthened from 2 to 3 weeks. In patients treated with infliximab, the dosing interval will be lengthened from 8 to 12 weeks. Consists of two groups: Patients randomised to the intervention group and patients allocated to the intervention group based on preference.

    Biological: Infliximab · Biological: Adalimumab

  • No intervention
    Control group

    Unchanged dosing interval. Consists of two groups: Patients randomised to the control group and patients allocated to the control group based on preference.

Interventions

  • BiologicalInfliximab

    Dosing interval lengthening from 8 to 12 weeks

    Also known as: Remicade, Flixabi, Inflectra, Remsima, Zessly

  • BiologicalAdalimumab

    Dosing interval lengthening from 2 to 3 weeks

    Also known as: Humira, AMGEVITA, Hulio, Hyrimoz, Idacio, Imraldi

06

What researchers measure

Primary outcomes

  1. cumulative incidence of out-of-range fecal calprotectin results at 48 weeks follow-up

    Out-of-range FC results are defined as fecal calprotectin above the target range (i.e. \>250 μg/g for CD patients; \>150 μg/g for UC patients) and at least 100 μg/g increase compared with the previous result, unless the previous result was already above the target range.

    Time frame: 48 weeks

Secondary outcomes

  1. Time to get out-of-range fecal calprotectin results

    The time from study baseline until the first out-of-range fecal calprotectin result

    Time frame: up to 48 weeks

  2. Cumulative incidence of anti-TNF-associated respiratory infections and dermatological adverse effects at 48 weeks follow-up

    Dermatological adverse effect include skin infections, new-onset or worsening of psoriasis, psoriasiform lesions, eczema, acne and alopecia

    Time frame: 48 weeks

  3. Evolution of FC and anti-TNF trough levels in the first 16 weeks after reverting to previous dosing interval

    Proportion of patients with return of FC levels to target range without switch to out-of-class biological

    Time frame: Up to 48+16 weeks

  4. Proportion of patients developing loss-of-response in the first 16 weeks after reverting to the previous dosing interval

    Loss-of-response is defined as the appearance of symptoms of active IBD in combination with persistent out-of-range fecal calprotectin results

    Time frame: Up to 48+16 weeks

  5. Identification of predictors of successful de-escalation.

    Predictors of successful de-escalation will be assessed by calculating odds ratios with the use of univariate logistic regression analysis. Candidate predictors with p\<0.10 in univariate analysis will be selected for use in the multivariate analysis.

    Time frame: 48 weeks

Other outcomes

  1. Patients' attitudes towards deprescribing anti-TNF agents

    We will use the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire

    Time frame: 48 weeks

07

Study locations

7 sites
08

References and documents

Publications

  • Bouhuys M, Lexmond WS, Dijkstra G, Lobaton T, Louis E, van Biervliet S, Groen H, Guardiola J, Rheenen PV. Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial. BMJ Open. 2021 Nov 3;11(11):e054154. doi: 10.1136/bmjopen-2021-054154. PubMed 34732500 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Mar 2026, 60 months after the start.

Of 33 non-industry phase 4 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 63. This study's planned 60 months is above that.

Counting every sponsor, half of 38 studies reached it within 38 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2020
First posted
Nov 27, 2020
StartActual
Mar 11, 2021
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Jan 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04646187
Collaborators
European Crohn´s and Colitis Organisation, Bühlmann Laboratories AG
Responsible party
P.F. van Rheenen (MD PhD, University Medical Center Groningen) — Principal investigator
First posted
Nov 27, 2020
Start date
Mar 11, 2021
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Jan 6, 2025

Study contacts

Patrick F van Rheenen, MD PhD
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Infliximab · Adalimumab

Start the discussion